Lack of effect of gastric acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir in HIV-infected patients

被引:10
作者
Chiu, Yi-Lin [1 ]
Klein, Cheri E. [1 ]
Woodward, William C. [1 ]
King, Kathryn R. [1 ]
Naylor, Christian [1 ]
Awni, Walid [1 ]
Brun, Scott [1 ]
机构
[1] Abbott Labs, Abbott Pk, IL 60064 USA
关键词
PROTON-PUMP INHIBITORS; DRUG-INTERACTIONS; ATAZANAVIR; OMEPRAZOLE; VOLUNTEERS; RITONAVIR; REGIMEN;
D O I
10.1089/apc.2006.0120
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Recent studies have shown that coadministration of certain protease inhibitors (PIs) with gastric acid-reducing agents results in decreased plasma concentrations of the PI. To assess the effect of acid-reducing agents on lopinavir/ritonavir, data from two clinical trials ( n = 38 and 190) were pooled. Both trials randomized antiretroviral-naive, HIV-infected patients to receive lopinavir/ritonavir 400/100 mg twice-daily or 800/200 mg once-daily in combination with stavudine and lamivudine, or tenofovir and emtricitabine. Concurrent administration of gastric acid-reducing agents including antacids of various brand names, proton pump inhibitors (omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole), and H-2-receptor antagonists (ranitidine, famotidine, cimetidine, and nizatidine) was reported in both trials. Lopinavir and ritonavir pharmacokinetic parameters were evaluated. Thirty subjects were considered users of acid-reducing agents at the times of pharmacokinetic evaluation. HIV-infected patients who received gastric acid-reducing agents during administration of lopinavir/ritonavir-based treatment regimens did not appear to have a reduction in lopinavir or ritonavir exposures.
引用
收藏
页码:247 / 251
页数:5
相关论文
共 15 条
[1]  
AGARWALA S, 2005, 12 C RETR OPP INF BO
[2]  
AGARWALA S, 2005, 6 INT WORKSH CLIN PH
[3]   Pharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor indinavir [J].
Burger, DM ;
Hugen, PWH ;
Kroon, FP ;
Groeneveld, P ;
Brinkman, K ;
Foudraine, NA ;
Sprenger, H ;
Koopmans, PP ;
Hekster, YA .
AIDS, 1998, 12 (15) :2080-2082
[4]   Once-daily versus twice-daily Lopinavir/Ritonavir in antiretroviral-naive HIV-positive patients: A 48-week randomized clinical trial [J].
Eron, JJ ;
Feinberg, J ;
Kessler, HA ;
Horowitz, HW ;
Witt, MD ;
Carpio, FF ;
Wheeler, DA ;
Ruane, P ;
Mildvan, D ;
Yangco, BG ;
Bertz, R ;
Bernstein, B ;
King, MS ;
Sun, E .
JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (02) :265-272
[5]   Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir [J].
Ford, SL ;
Wire, MB ;
Lou, Y ;
Baker, KL ;
Stein, DS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (01) :467-469
[6]   Proton pump inhibitors do not reduce atazanavir concentrations in HIV-infected patients treated with ritonavir-boosted atazanavir [J].
Guiard-Schmid, JB ;
Poirier, JM ;
Bonnard, P ;
Meynard, JL ;
Slama, L ;
Lukiana, T ;
Jaillon, P ;
Pialoux, G .
AIDS, 2005, 19 (16) :1937-1938
[7]  
Humphries TJ, 1999, ALIMENT PHARM THER, V13, P18
[8]   A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen [J].
Johnson, Margaret A. ;
Gathe, Joseph C., Jr. ;
Podzamczer, Daniel ;
Molina, Jean-Michel ;
Naylor, Christian T. ;
Chiu, Yi-Lin ;
King, Martin S. ;
Podsadecki, Thomas J. ;
Hanna, George J. ;
Brun, Scott C. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 43 (02) :153-160
[9]   Co-administration of atazanavir with proton-pump inhibitors and H2 blockers [J].
Khanlou, L ;
Farthing, C .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 39 (04) :503-503
[10]  
LUBER A, 2004, 7 INT C DRUG THER HI